Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
In conjunction with prevention efforts, the introduction of screening examinations has resulted in a reduction of nearly 6 million cancer-related deaths since 1975.
Breast density is most often discussed within the context of cancer risk, but new research suggests that it also could be used as a marker of cardiometabolic health.
The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.
Varian Medical Systems Inc. is expanding deployment of its SmartConnect technology to provide remote customer support for users of the company's Acuity system for planning, simulating, and verifying radiotherapy treatment plans.
Misys Healthcare Systems is advancing the CPR (computerized patient record) and CPOE (computerized physician order entry) capabilities of a New Jersey-based community hospital.
Group purchasing organization Consorta Inc. signed a contract with Elekta Inc. for its broad range of stereotactic radiosurgery and associated neuroscience products.
EMC Corp. deployed its content addressed storage (CAS) platform at the Saint Raphael Healthcare System, a 511-bed academic health science center affiliated with Yale University School of Medicine.
RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.
Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.
A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.
